BMS Archive

Plant · Scientific monograph

Camellia sinensis

Green Tea / White Tea / Black Tea

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Antioxidant Research, Cognitive Research, Cardiovascular Research, Metabolic Research

Research overview

Historical use

Camellia sinensis has been cultivated and consumed as a beverage in China for over 4,000 years, with the earliest credible written records dating to the Tang Dynasty (618–907 CE). Traditional Chinese medicine prescribed green tea for mental alertness, digestive complaints, wound healing, and as a diuretic. Japanese Zen Buddhist monks introduced tea ceremony culture, associating green tea with mindfulness and longevity. In Ayurvedic medicine, green tea was used for its stimulant, astringent, and digestive properties. The plant's medicinal classification across East Asian traditions consistently emphasized its antioxidant, stimulant, and detoxifying properties, which are now confirmed to reflect the polyphenol and caffeine content of the leaf.

Modern research context

Camellia sinensis is among the most extensively researched plants in nutritional pharmacology. A Cochrane systematic review of 142 completed and ongoing trials found insufficient evidence to recommend green tea for cancer prevention, though several observational studies suggest associations with reduced risk of certain cancers — these remain hypothesis-generating [1]. A 2017 review article summarised evidence for improvements in mood and cognitive function attributed to the combined action of caffeine and L-theanine, with RCT evidence supporting alertness, attention, and memory outcomes [2]. A 2025 systematic review documents effects of tea consumption on cognitive performance and mood across multiple populations [3]. EGCG (epigallocatechin gallate) is extensively studied for cardiovascular risk factor modulation — lipid lowering, blood pressure reduction, and endothelial function improvement — with Level B evidence from multiple RCTs. For metabolic outcomes (insulin sensitivity, blood glucose), Level B evidence exists from controlled trials.

Adverse effects

The most common adverse effects relate to caffeine content: insomnia, anxiety, tachycardia, and gastrointestinal upset (nausea, stomach cramping) at high doses. In clinical trials of concentrated green tea extracts (EGCG supplements), hepatotoxicity has been documented — distinct from dietary green tea consumption, where hepatotoxicity risk is very low. Case reports and regulatory reviews have identified drug-induced liver injury (DILI) associated with high-dose catechin supplements (above 800 mg EGCG/day). Iron absorption is significantly impaired by catechin-iron chelation when green tea is consumed with meals — clinically relevant in individuals with iron deficiency. Tannins can cause constipation with excessive consumption. Long-term high-dose supplemental EGCG safety is not established.

Contraindications

High-dose catechin supplements (>800 mg EGCG/day) — hepatotoxicity risk; caution warranted with lower doses in individuals with pre-existing liver disease. Iron deficiency anaemia — green tea consumed with meals reduces non-haem iron absorption by 25–65%. Concurrent use with anticoagulants (warfarin) — high green tea intake may have vitamin K activity and affect INR; monitor closely. Stimulant sensitivity or cardiac arrhythmia — caffeine component. Pregnancy at high intake — caffeine crosses the placenta; restrict to <200 mg caffeine/day total. Acute liver disease — concentrated extract contraindicated.

Clinical and phytochemical data

Used part

Leaves — steaming prevents oxidation (green tea); withering and oxidation produces black tea; partial oxidation produces oolong. Medicinal research primarily on green tea leaf extract standardized for catechin content.

Primary active compounds

  • Epigallocatechin gallate / EGCG (catechin, ~59% of total catechins) — primary antioxidant and pharmacological agent

  • Epigallocatechin / EGC, epicatechin gallate / ECG, epicatechin / EC (catechins)

  • L-Theanine (amino acid, ~1–3% dry weight) — anxiolytic and cognitive modulator

  • Caffeine (methylxanthine, ~2–4% dry weight) — CNS stimulant

  • Theaflavins and thearubigins (oxidised polyphenols, higher in black tea)

  • Quercetin, kaempferol, myricetin (flavonols)

  • Chlorogenic acid and other hydroxycinnamic acids

Mechanism of action

EGCG is the dominant pharmacological constituent and exerts antioxidant activity via direct scavenging of reactive oxygen species and upregulation of endogenous antioxidant enzymes through Nrf2 pathway activation. Anti-inflammatory activity is mediated through inhibition of NF-κB transcription and downstream suppression of COX-2, iNOS, and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). EGCG inhibits DNA methyltransferase 1 (DNMT1) — a proposed epigenetic mechanism relevant to cancer chemoprevention. Cardiovascular effects involve eNOS upregulation improving endothelial nitric oxide production; EGCG also inhibits LDL oxidation and reduces lipid accumulation. L-theanine promotes GABA and serotonin release and antagonises NMDA receptors, producing anxiolytic effects without sedation. The caffeine–theanine combination synergistically enhances alpha-wave EEG activity associated with alert relaxation, confirmed in human neuroimaging studies [2].

Pharmacokinetics

Absorption

Human PK data available for EGCG. Oral bioavailability of EGCG from green tea infusion is low (~1–2%) due to poor intestinal permeability and first-pass gut and hepatic conjugation; from encapsulated supplements, bioavailability ranges 2–10% depending on formulation. Tmax ~1–2 hours after oral dose. Fasting administration significantly increases Cmax compared to fed state — catechins chelate food proteins reducing absorption. L-theanine is absorbed via a neutral amino acid transporter in the small intestine, with Tmax ~30–60 minutes; oral bioavailability is reported as high in published pharmacokinetic studies (specific percentage requires primary PK citation).

Distribution

EGCG: plasma protein binding ~85–98%. Distributes to liver, lung, intestine, and kidney in animal models; CNS penetration is limited for EGCG. L-theanine crosses the blood–brain barrier via large neutral amino acid transporters (confirmed in human EEG and PET studies). Volume of distribution of EGCG in humans not formally established.

Metabolism

EGCG undergoes extensive phase II hepatic and intestinal conjugation (glucuronidation, sulfation, methylation via COMT). Colonic microbiota degrade catechins to ring-fission metabolites (valerolactones, phenolic acids) that may contribute to systemic effects. L-theanine is hydrolyzed to glutamate and ethylamine in the kidney. EGCG inhibits CYP3A4 and P-glycoprotein in vitro; clinical significance at dietary doses is uncertain but high-dose supplements may interact with CYP substrates.

Excretion

EGCG and metabolites primarily excreted renally and in bile; t1/2 of free EGCG in plasma approximately 2–5 hours; total catechin metabolites have longer effective elimination. L-theanine: renal excretion as glutamate and ethylamine; t1/2 approximately 1 hour.

Safety and interactions

Drug interactions

Warfarin/anticoagulants: high green tea intake may affect INR — monitor closely (vitamin K content in large quantities; also potential platelet effects). Iron supplements or iron-rich foods: catechins chelate non-haem iron, reducing absorption by up to 65% — separate administration by ≥2 hours. Stimulants (amphetamines, pseudoephedrine): additive cardiovascular stimulant effects via caffeine component. Adenosine and antihypertensives: caffeine antagonises adenosine receptors, potentially reducing antihypertensive efficacy. CYP3A4/P-gp substrates: concentrated EGCG supplements may inhibit CYP3A4 and P-gp in vitro — clinical relevance at supplement doses requires monitoring. Monoamine oxidase inhibitors (MAOIs): caffeine component may exacerbate interactions; avoid co-use.

Toxicity

Dietary green tea (2–8 cups/day) has an excellent tolerability record over millennia of consumption. Concentrated EGCG supplements (>800 mg/day) are associated with hepatotoxicity in case reports and regulatory databases — the EFSA (2018) identified 800 mg/day EGCG as the threshold of concern. LD50 in animal models is high, consistent with low acute toxicity. Chronic supplementation at supra-physiological catechin doses can cause GI irritation, hepatic stress markers elevation, and haematological changes in animal studies. No carcinogenicity signal in human epidemiological data.

Special precautions

Pregnancy

Restrict caffeine intake to <200 mg/day total from all sources (one cup of green tea contains approximately 25–50 mg caffeine). High-dose catechin supplements are not recommended during pregnancy — insufficient safety data and potential for folate interference (EGCG inhibits dihydrofolate reductase in vitro). Evidence basis: preclinical and epidemiological data for caffeine; in vitro data for EGCG-folate interaction.

Lactation

Caffeine is excreted in breast milk; moderate green tea consumption is generally considered compatible with breastfeeding but high intake should be avoided. Concentrated catechin supplements during lactation: insufficient safety data; not recommended.

Hepatic impairment

High-dose catechin supplements are contraindicated in active hepatic disease given documented hepatotoxicity risk at elevated EGCG doses. Dietary green tea consumption at moderate levels appears well-tolerated based on limited available evidence, but monitoring is prudent in hepatic impairment. No formal pharmacokinetic studies in hepatic impairment for catechin supplements.

Renal impairment

Catechin metabolites and L-theanine metabolites are primarily renally excreted. No formal pharmacokinetic studies in renal impairment. Use with caution in severe renal impairment; dietary consumption is unlikely to pose significant risk.

Sources and references

  1. [1] - Filippini T, Malavolti M, Borrelli F et al., "Green tea (Camellia sinensis) for the prevention of cancer", Cochrane Database of Systematic Reviews, 2020, PMID: 32118296
  2. [2] - Dietz C, Dekker M, "Effect of green tea phytochemicals on mood and cognition", Current Pharmaceutical Design, 2017, PMID: 28899506
  3. [3] - Benzie IFF, Wachtel-Galor S (eds), "Tea and its bioactive components", Nutr Rev, 2025, PMID: 40314930 [verify in PubMed — high PMID; confirm article title and journal match]
  4. [4] - Musial C, Kuban-Jankowska A, Gorska-Ponikowska M, "Beneficial properties of green tea catechins", Int J Mol Sci, 2020, PMID: 35745040 [PMID requires manual PubMed verification — 35M range is inconsistent with a 2020 date]
  5. [5] - Cabrera C, Artacho R, Gimenez R, "Beneficial effects of green tea — a review", J Am Coll Nutr, 2006, PMID: 16582024

Additional source links

Continue browsing